The primary challenge to address is targeting IL-2 to the tumor to prolong its effect at this specific site; this to limit IL-2’s interaction with the α-chain of IL-2R on endothelial and pulmonary cells, which can lead to severe, life-threatening effects [63,64,65,66]. The gene discussed is IL2; the disease is neoplasm.